Air Quality and Respiratory Disease

Air quality and respiratory disease concerns the epidemiologic relationship between airborne pollutants — particulate matter, ozone, nitrogen dioxide, sulphur dioxide, and others — and disease of the lungs and airways, as well as broader cardiopulmonary outcomes. It distinguishes short-term effects, visible as day-to-day fluctuations in mortality and hospital admissions, from long-term effects estimated in cohorts followed for years.

Definition

The topic addresses the study of how exposure to ambient and indoor air pollutants relates to respiratory and cardiopulmonary disease, including both transient responses to short-term exposure and the chronic disease burden associated with long-term exposure.

Scope

The topic covers the principal pollutants, the time-series and cohort designs used to measure their health effects, and the contrast between acute and chronic exposure. It is a reference treatment of how pollution-health associations are quantified and does not constitute clinical or air-quality regulatory advice.

Key concepts

• Particulate matter (PM2.5, PM10)
• Fine and ultrafine particles
• Time-series mortality studies
• Long-term cohort exposure
• Concentration-response function
• Acute versus chronic effects
• Household (indoor) air pollution

Mechanisms

Inhaled particles and gases deposit in the airways and alveoli, where the finest fractions can reach the deep lung and enter the circulation, provoking airway and systemic inflammation and oxidative stress. These responses are linked to exacerbations of asthma and chronic obstructive pulmonary disease, impaired lung development, lung cancer, and cardiovascular events. Epidemiologically, short-term effects are captured by time-series studies relating daily pollution to daily mortality and admissions, while long-term effects are estimated by following large cohorts across areas with differing concentrations and fitting concentration-response functions.

Clinical relevance

Air pollution is a recognised driver of respiratory and cardiovascular morbidity and mortality and a major target of public-health and environmental policy. This entry describes how those population-level associations are established and is not a basis for individual diagnosis or treatment.

Epidemiology

Long-term cohort analysis by Pope and colleagues found that each increment in fine particulate concentration was associated with measurable increases in cardiopulmonary and lung-cancer mortality, and time-series meta-analysis by Atkinson and colleagues confirmed consistent short-term associations between PM2.5 and daily mortality and hospital admissions. The Lancet Commission on pollution and health identified ambient and household air pollution as leading environmental contributors to the global burden of non-communicable disease.

History

Severe pollution episodes — most notably the London smog of December 1952, associated with thousands of excess deaths — established air pollution as a public-health hazard. From the 1990s, large prospective cohorts such as the Harvard Six Cities and the American Cancer Society study demonstrated that chronic exposure to fine particles, even at moderate concentrations, was associated with increased mortality, shaping modern air-quality science.

Key figures

• C. Arden Pope III
• Joel Schwartz
• Richard Atkinson
• Douglas Dockery

Seminal works

• pope-2002
• atkinson-2014

Frequently asked questions

Why is fine particulate matter (PM2.5) of particular concern?

Fine particles are small enough to penetrate deep into the lungs and reach the bloodstream, and cohort studies have linked long-term PM2.5 exposure to increased cardiopulmonary and lung-cancer mortality even at moderate concentrations.

What is the difference between time-series and cohort studies of air pollution?

Time-series studies relate short-term, day-to-day changes in pollution to acute changes in mortality and hospital admissions, whereas cohort studies follow populations over years to estimate the chronic disease effects of long-term exposure.